Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03640052 · ClinicalTrials.gov registry record · Phase 1
Pharmacological Activation of HMN for OSA
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03640052 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 6 participants.
The verdict
NCT03640052, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of LTM1201L, LTM1201LN, LTM1201LB, LTM1201LD administered before sleep on OSA phenotype traits and OSA severity during sleep.
Interventions
- DRUG Placebo oral capsule
- DRUG LTM1201L
- DRUG LTM1201LN
- DRUG LTM1201LB
- DRUG LTM1201LD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03640052
The ClinicalTrials.gov registry entry for NCT03640052 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo oral capsule is the first listed.
NCT03640052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03640052 about?
NCT03640052 is a clinical study titled "Pharmacological Activation of HMN for OSA". Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In th...
What is the current status of trial NCT03640052?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2018-10-30. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03640052?
The interventions under investigation include: Placebo oral capsule (DRUG), LTM1201L (DRUG), LTM1201LN (DRUG), LTM1201LB (DRUG), LTM1201LD (DRUG).
Who is sponsoring clinical trial NCT03640052?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.